The bill amends the "Right to Try Act" to expand access to experimental treatments for patients with advanced, life-threatening, or severely debilitating illnesses. It introduces new definitions and clarifications regarding eligible patients and facilities, as well as the conditions under which investigational drugs, biological products, or devices can be provided. Notably, the bill specifies that health care providers cannot face sanctions for recommending or providing these treatments, and it outlines the responsibilities of health insurers regarding coverage for such treatments.

Additionally, the bill establishes that manufacturers of investigational treatments are not required to provide these treatments to patients but may do so without compensation or may charge for associated costs. It also protects patients' heirs from liability for debts related to treatments if the patient dies while receiving them. The legislation further ensures that state officials cannot obstruct access to these treatments and clarifies that no private cause of action can be brought against manufacturers or providers for harm resulting from the use of investigational treatments, provided they comply with the act's terms.

Statutes affected:
House Introduced Bill: 333.26451